Patent intelligence · US
US 6515003
Heterocyclic derivatives for the treatment of diabetes and other diseases
Heterocyclic derivatives for the treatment of diabetes and other diseases
Patent details — US 6515003
- Jurisdiction
- US
- Status
- expired
- Grant date
- Feb 4, 2003
- Expiration
- Jan 30, 2023
- Applicant
- Maxim Pharmaceuticals, Inc.
- Claims
- 23
- CPC classes
- A61P, A61P1/00, A61P1/04, A61P11/00
Quick answer
US 6515003 (Heterocyclic derivatives for the treatment of diabetes and other diseases) is held by Maxim Pharmaceuticals, Inc.. Status: expired. Granted Feb 4, 2003. Expires Jan 30, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Maxim Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61P, A61P1/00, A61P1/04, A61P11/00, A61P15/00, A61P19/02
More from Maxim Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12391732
Articles comprising a silk polypeptide for antigen delivery
granted -
US 12379385
Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
granted -
US 12318397
Methods and compositions for testosterone production
granted -
US 12290524
Methods and compositions for testosterone production
granted -
US 12171837
Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
granted -
US 12168718
Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel
granted -
US 12144876
Security mechanisms for radiopharmaceutical elution system and elution process
granted -
US 12133890
Antigen-binding polypeptide targeting B7H3 and application thereof
granted
Frequently asked questions
What is US patent 6515003?
US 6515003 (Heterocyclic derivatives for the treatment of diabetes and other diseases) is held by Maxim Pharmaceuticals, Inc.. Status: expired. Granted Feb 4, 2003. Expires Jan 30, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6515003?
Maxim Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.
When does US 6515003 expire?
Our index shows an expiration date of Jan 30, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.